Catalyst Pharmaceutical Partners to Present at 15th Annual BIO CEO & Investor Conference

Catalyst Pharmaceutical Partners to Present at 15th Annual BIO CEO & Investor
Conference

CORAL GABLES, Fla., Feb. 5, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical
Partners, Inc. (Nasdaq:CPRX) announced today that the company will present at
the 15^th Annual BIO CEO & Investor Conference, being held at the Waldorf
Astoria Hotel in New York City, New York. Patrick J. McEnany, Catalyst's Chief
Executive Officer and Steven Miller, PhD, Catalyst's Chief Scientific
Officer/COO, will provide an overview of the company and its progress in key
programs on Monday, February 11, 2013, at 4:00 p.m. Eastern Standard Time. The
company's presentation materials will be posted at the company's website,
http://www.catalystpharma.com, in the Investors section, under "Events and
Presentations".

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc. is a specialty pharmaceutical company
focused on the development and commercialization of prescription drugs
targeting rare (orphan) neurological diseases and disorders, including
Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette
Syndrome. Catalyst's lead candidate, Firdapse™ for the treatment of LEMS, is
currently undergoing testing in a global, multi-center, pivotal phase III
trial. Catalyst is also developing a potentially safer and more potent
vigabatrin analog (designated CPP-115 by Catalyst) to treat infantile spasms,
and epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette Syndrome,
and movement disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking
statements involve known and unknown risks and uncertainties, which may cause
the Company's actual results in future periods to differ materially from
forecasted results. A number of factors, including whether any of the
Company's product candidates will ever be approved for commercialization and
those factors described in the Company's filings with the U.S. Securities and
Exchange Commission (SEC), could adversely affect the Company. Copies of the
Company's filings with the SEC are available from the SEC, may be found on the
Company's website or may be obtained upon request from the Company. The
Company does not undertake any obligation to update the information contained
herein, which speaks only as of this date.

CONTACT: Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         pmcenany@catalystpharma.com
        
         Melody Carey
         Rx Communications Group
         Co-President
         (917) 322-2571
         mcarey@rxir.com